Palbociclib in Breast Cancer: New Overall Survival Data

Share this post

Final results from the PALOMA 3 study show that addition of palbociclib to fulvestrant improves overall survival by 7 months, but the result was not statistically significant. So now what?
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply